Sekine, I., Ichinose, Y., Nishiwaki, Y., Yamamoto, N., Tsuboi, M., Nakagawa, K., ...
Background: This report describes quality of life (QoL) findings of a randomized study comparing gefitinib with docetaxel in patients with advanced/metastatic pretreated non-small-cell lung cancer....
Segawa, Y., Aogi, K., Inoue, K., Sano, M., Sekine, I., Tokuda, Y., ...
Background: The 5-HT3 receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV)....
Maemondo, M., Masuda, N., Sekine, I., Kubota, K., Segawa, Y., Shibuya, M., ...
Background: This is a randomized, double-blind, dose-ranging study in patients receiving highly emetogenic chemotherapy (HEC) to evaluate the safety, efficacy, and pharmacokinetics of palonosetron,...
Sekine, I., Nishiwaki, Y., Noda, K., Kudoh, S., Fukuoka, M., Mori, K., ...
Background: The purpose of this study was to evaluate the toxicity and antitumor effect of cisplatin, irinotecan and etoposide combinations on two schedules, arms A and B, for previously untreated...
Sekine, I., Yamamoto, N., Kunitoh, H., Ohe, Y., Tamura, T., Kodama, T., ...
Background: Although the evaluation of new investigational drugs in phase I, II and III trials requires considerable time and patient resources, only a few of these drugs are ultimately established...
Background The efficacies and toxicities of anticancer agents vary greatly among patients This is attributable to the activities of drug-metabolizing enzymes and membrane transporters, primarily...
Sekine, I., Tamura, T., Kunitoh, H., Kubota, K., Shinkai, T., Kamiya, Y., ...
Background: Although the potential activity of anticancer agents has been traditionally assessed by the response rate (RR) in phase II trials, there is an increasing need to identify alternative...
Recurrence of a germ cell tumor 12 years after initial treatment: a case report (1998)
Sekine, I, Sasaki, Y, Hasebe, T, Mukai, K, Kinoshita, T, Amano, A, ...
Sekine, I., Kubota, K., Nishiwaki, Y., Sasaki, Y., Tamura, T., Saijo, N.
Background: Response rate (RR) has been used as a defining endpoint of new-agent phase II trials for non-small-cell lung cancer (NSCLC). However, tumor responses to chemotherapy do not always result...
Second-line chemotherapy for relapsed small cell lung cancer (1997)
Ebi, N, Kubota, K, Nishiwaki, Y, Hojo, F, Matsumoto, T, Kakinuma, R, ...
Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Hojo, F, Matsumoto, T, ...
Expression of parathyroid hormone related peptide in human pituitary tumours.
Ito, M, Enomoto, H, Usa, T, Villadolid, M C, Ohtsuru, A, Namba, H, ...
The presence of parathyroid hormone related peptide (PTHrP) was studied in 20 patients with pituitary adenomas and one patient with pituitary adenocarcinoma. PTHrP expression was shown in almost all...
Expression of parathyroid hormone related peptide in human pituitary tumours.
Ito, M, Enomoto, H, Usa, T, Villadolid, M C, Ohtsuru, A, Namba, H, ...
The presence of parathyroid hormone related peptide (PTHrP) was studied in 20 patients with pituitary adenomas and one patient with pituitary adenocarcinoma. PTHrP expression was shown in almost all...
Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion.
Nakayama, T., Ito, M., Ohtsuru, A., Naito, S., Nakashima, M., Fagin, J. A., ...
The proto-oncogene Ets-1 is a transcription factor known to control the expression of a number of genes involved in extracellular matrix remodeling and has been postulated to play a role in cell...
Hamanaka, Y, Nakashima, M, Wada, A, Ito, M, Kurazono, H, Hojo, H, ...
BACKGROUND—Human β-defensin 2 (hBD-2) plays a role in the innate defence system at mucosal surfaces. Colonisation of Helicobacter pylori in the stomach is an important pathological factor in...
Circulating endothelial cells in Kawasaki disease
Nakatani, K, Takeshita, S, Tsujimoto, H, Kawamura, Y, Tokutomi, T, Sekine, I
Recent reports have demonstrated that circulating endothelial cells (CECs) are observed in several diseases with vascular injury. Because Kawasaki disease (KD) is one type of systemic vasculitis, we...
Circulating soluble selectins in Kawasaki disease
TAKESHITA, S, DOBASHI, H, NAKATANI, K, KOIKE, Y, TSUJIMOTO, H, HIRAYAMA, K, ...
To investigate the significance of circulating adhesion molecules associated with leucocyte–endothelial cell interaction in Kawasaki disease (KD), serum levels of soluble E-, P-, L-selectin (sE-,...
Takata, Y, Seki, S, Dobashi, H, Takeshita, S, Nakatani, K, Kamezawa, Y, ...
The aim of this study was to further assess the role of pooled human immunoglobulin (PHIG) on cytokine production from PBMC stimulated with a bacterial superantigen. Human PBMC were cultured with...
Nakatani, K, Takeshita, S, Tsujimoto, H, Kawamura, Y, Kawase, H, Sekine, I
To investigate the regulation of Fcγ receptor (FcγR) expression on circulating phagocytes in Kawasaki disease (KD), we analysed the expressions of FcγRI, II and III on neutrophils and monocytes in...
Increased levels of circulating soluble CD14 in Kawasaki disease
Takeshita, S, Nakatani, K, Tsujimoto, H, Kawamura, Y, Kawase, H, Sekine, I
The CD14 molecule, which is known to be a receptor for endotoxin, is expressed on monocytes and neutrophils. It is found as a soluble CD14 (sCD14) in circulation, and the plasma level has been shown...
Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease
Takeshita, S, Tokutomi, T, Kawase, H, Nakatani, K, Tsujimoto, H, Kawamura, Y, ...
Matrix metalloproteinases (MMPs) play an important role in the progression of tumour cells and the invasion of inflammatory cells by degrading the extracellular matrix. In the MMP family, MMP-9...
Delayed apoptosis of circulating neutrophils in Kawasaki disease
Tsujimoto, H, Takeshita, S, Nakatani, K, Kawamura, Y, Tokutomi, T, Sekine, I
Circulating polymorphonuclear neutrophils (PMNs) are known to increase in number and are functionally activated in the acute phase of Kawasaki disease (KD). In the present study, we investigated...
NAKATANI, K, TAKESHITA, S, TSUJIMOTO, H, SEKINE, I
Endothelial cells (ECs) are a target in inflammation, and the death of EC is regulated by various factors. Although intravenous immunoglobulin (IVIG) preparations are known to be beneficial...
KOIKE, Y, SEKI, S, OHKAWA, T, KANEKO, T, KOGAWA, K, FUJITSUKA, S, ...
To clarify the immune response of CD57+ T cells (most of them are CD8+) in peripheral blood (PB) against alloantigens in order to elucidate the T helper 1 (Th 1) immune response, we assessed the role...
Kusaba, T, Nakayama, T, Yamazumi, K, Yakata, Y, Yoshizaki, A, Nagayasu, T, ...
Background: The signal transducer and activator of transcription 3 (STAT3) is a key signalling molecule implicated in the regulation of growth and malignant transformation. Constitutive activation of...
Suzuki, K., Ogura, T., Yokose, T., Sekine, I., Nagai, K., Kodama, T., ...
There is accumulating evidence of an increased risk of familial clustering of cancer in the first-degree relatives of lung cancer probands. However, no explanation has been proposed for these...
Sekine, I., Nishiwaki, Y., Kakinuma, R., Kubota, K., Hojo, F., Matsumoto, T., ...
Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with...
Ando, M., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., Yamamoto, N., ...
We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over 90 min on...
Sekine, I, Nokihara, H, Takeda, K, Nishiwaki, Y, Nakagawa, K, Isobe, H, ...
Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mg m−2 on days 1 and 8 and cisplatin 60 mg m−2 on day 1 with (n=55) or without...
Goto, K, Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Matsumoto, T, ...
Sekine, I, Nishiwaki, Y, Kakinuma, R, Kubota, K, Hojo, F, Matsumoto, T, ...